Vor Biopharma’s (VOR) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research note released on Thursday morning,RTT News reports. Wedbush currently has a $7.00 price target on the stock.

VOR has been the topic of a number of other reports. JMP Securities restated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma presently has a consensus rating of “Buy” and an average price target of $8.86.

Vor Biopharma Stock Up 2.1 %

Shares of VOR stock opened at $0.87 on Thursday. The business has a fifty day simple moving average of $1.22 and a 200 day simple moving average of $1.01. The company has a market cap of $59.75 million, a P/E ratio of -0.53 and a beta of -0.40. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $2.43.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in VOR. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Vor Biopharma during the fourth quarter worth $33,000. Virtu Financial LLC bought a new position in Vor Biopharma during the 4th quarter worth $60,000. XTX Topco Ltd acquired a new position in Vor Biopharma during the 4th quarter worth about $80,000. Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma in the fourth quarter valued at about $102,000. Finally, Northern Trust Corp raised its position in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after acquiring an additional 44,252 shares during the last quarter. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.